Loading news...
The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite. The index's top payers dish up to 6.8%.
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its single share price. Analyst projections suggest the top ten Dow Dogs could deliver an average 23.55% net gain by January 2027, with varying risk profiles. Yield-based strategies favor underdogs; price drops or dividend hikes could bring more Dow Dogs into fair-value territory for income-focused investors.
Ferguson Wellman Capital Management Inc. grew its position in shares of Amgen Inc. (NASDAQ: AMGN) by 2.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 307,566 shares of the medical research company's stock after purchasing an additional 7,988 shares during the quarter.
In the closing of the recent trading day, Amgen (AMGN) stood at $330.05, denoting a -3.39% move from the preceding trading day.
Building on a strong 2025, CVS Health's outlook for 2026 and beyond looks promising. Amgen is developing newer drug products that will address a recent patent cliff.
CoreCap Advisors LLC reduced its position in shares of Amgen Inc. (NASDAQ: AMGN) by 26.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,094 shares of the medical research company's stock after selling 2,867 shares during the period. CoreCap Advisors LLC's
THOUSAND OAKS, Calif., Jan. 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2026 J.P.
On Tuesday, Amgen Inc. (NASDAQ: AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines.
AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.
CX Institutional increased its stake in Amgen Inc. (NASDAQ: AMGN) by 9.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,960 shares of the medical research company's stock after buying an additional 3,590 shares during
Cerity Partners LLC reduced its stake in Amgen Inc. (NASDAQ: AMGN) by 1.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 416,182 shares of the medical research company's stock after selling 6,837 shares during the period. Cerity Partners
Amgen (AMGN) has agreed to acquire UK-based cancer drug developer Dark Blue Therapeutics in a deal valued at up to $840 million, as the company looks to reinfor
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd.
In the closing of the recent trading day, Amgen (AMGN) stood at $320.71, denoting a -2.12% move from the preceding trading day.
Railway Pension Investments Ltd raised its stake in Amgen Inc. (NASDAQ: AMGN) by 9.3% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,300 shares of the medical research company's stock after acquiring an additional 8,200 shares during the period.
Davis Capital Management bought a new stake in shares of Amgen Inc. (NASDAQ: AMGN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 6,523 shares of the medical research company's stock, valued at approximately $1,841,000. Amgen accounts for about 1.3% of
The 10 highest paying dividend stocks in the Dow Jones Industrial Average offer yields from 2.5% to 6.8%. A look at the Dogs of the Dow.
Econ Financial Services Corp increased its position in shares of Amgen Inc. (NASDAQ: AMGN) by 63.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,820 shares of the medical research company's stock after buying an additional 2,643 shares during the quarter. Econ
Braun Stacey Associates Inc. reduced its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 88.6% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,500 shares of the medical research company's stock after selling 34,949 shares during the quarter. Braun